
Arjun Lakshman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1875996/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia, 2019, 33, 2266-2275.	7.2	385
2	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	6.2	171
3	Natural history of t(11;14) multiple myeloma. Leukemia, 2018, 32, 131-138.	7.2	67
4	Efficacy of VDT PACEâ€like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	4.1	49
5	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	5.2	41
6	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
7	Genomics of rare genetic diseases—experiences from India. Human Genomics, 2019, 13, 52.	2.9	30
8	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	7.2	28
9	Efficacy of daratumumabâ€based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	4.1	25
10	Prevalence and Risk Factors of Hypertension among Male Occupational Bus Drivers in North Kerala, South India: A Cross-Sectional Study. ISRN Preventive Medicine, 2014, 2014, 1-9.	1.7	24
11	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	5.2	23
12	Chimeric antigen receptor Tâ€cells, bispecific antibodies, and antibodyâ€drug conjugates for multiple myeloma: An update. American Journal of Hematology, 2022, 97, 99-118.	4.1	23
13	Overall survival of patients with tripleâ€class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <scp>MAMMOTH</scp> . American Journal of Hematology, 2021, 96, E5-E8.	4.1	20
14	Antisynthetase syndrome: An under-recognized cause of interstitial lung disease. Lung India, 2016, 33, 20.	0.7	20
15	Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical) Tj ETQq1 Bortezomib-Based Induction. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 513-519.e1.	1 0.784314 0.4	rgBT /Overlo 14
16	Elevated cardiac biomarkers and echocardiographic left ventricular dysfunction at admission in patients with dengue fever: report from a tertiary care center in Northwest India. Tropical Doctor, 2018, 48, 261-265.	0.5	10
17	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. Blood, 2018, 132, 2015-2015.	1.4	10
18	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. Blood, 2019, 134, 3125-3125.	1.4	10

Arjun Lakshman

#	Article	IF	CITATIONS
19	Pharmacokinetics of High-Dose Propylene Glycol–Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1610-1614.	2.0	8
20	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. Blood, 2018, 132, 3233-3233.	1.4	6
21	Miliary tuberculosis in an Indian lady: Looking beyond miliary tuberculosis. Lung India, 2015, 32, 492.	0.7	4
22	Knuckle Pigmentation: A Clue to Systemic Illness. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 507-508.	0.6	2
23	Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'. Leukemia, 2018, 32, 2083-2085.	7.2	2
24	Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e115-e116.	0.4	2
25	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	1.4	2
26	Predictive Value of Glycated Hemoglobin and Body Mass Index for Pretreatment Neuropathy in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 89-95.	0.4	1
27	A Curious Case of "Septic Shockâ€: Journal of Emergency Medicine, 2017, 52, e61-e63.	0.7	1
28	Pachymeningeal Involvement with Blindness as the Presenting Manifestation of Non-Hodgkin Lymphoma. Turkish Journal of Haematology, 2018, 35, 73-74.	0.5	1
29	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. Blood, 2018, 132, 3303-3303.	1.4	1
30	Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma. Blood, 2019, 134, 5200-5200.	1.4	1
31	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM) Journal of Clinical Oncology, 2017, 35, 8038-8038.	1.6	1
32	ECG In Evaluation for Pulmonary Thromboembolism- Occam's Razor or Hickam's Dictum?. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, OJ01.	0.8	1
33	Natural history of t(11;14) multiple myeloma (MM) Journal of Clinical Oncology, 2017, 35, 8014-8014.	1.6	1
34	A Cutaneous Clue to a Systemic Illness. Clinical Infectious Diseases, 2015, 60, 1864-1865.	5.8	0
35	Hypereosinophilia in a Young Patient: Occam's Razor or Hickam's Dictum?. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 340-343.	0.6	0
36	Osteonecrosis, splenic calcification and sickle cell disease. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 463-464.	0.5	0

Arjun Lakshman

#	Article	IF	CITATIONS
37	Cannon Ball Lung Metastases from a Previously Unreported Primary. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, OJ01.	0.8	Ο
38	Natural history of delp53 multiple myeloma Journal of Clinical Oncology, 2018, 36, e20017-e20017.	1.6	0
39	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	1.4	Ο
40	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	1.4	0